Overview

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine predictive value of Hammersmith score on Complete Cytogenetic Response (CCyR).
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Dasatinib
Imatinib Mesylate